FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileObsidian Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
OBX
Obsidian Therapeutics Inc. Stock AnalysisComprehensive stock analysis for Obsidian Therapeutics Inc. (OBX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisOBX
OBX
Obsidian Therapeutics Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
OBX
  1. Home
  2. Stocks
  3. Obsidian Therapeutics Inc.
OB

Obsidian Therapeutics Inc.

🇺🇸OBX•NASDAQ
OB

Obsidian Therapeutics Inc.

🇺🇸OBX•NASDAQ
Market cap
$12.70M
P/E ratio
0.08

Your view on OBX

Mkt Cap
$12.70M
P/E
0.08
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Obsidian Therapeutics Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Not available
Headquarters
1030 Massachusetts Avenue, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Not available
Headquarters
1030 Massachusetts Avenue, Cambridge, MA, US
Description

A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors.

Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Obsidian Therapeutics Inc.. Starting points for Obsidian Therapeutics Inc.: P/E 0.1, EPS $1.39, beta 2.64 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Obsidian Therapeutics Inc.. Trailing twelve-month EPS for Obsidian Therapeutics Inc. stands at $1.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
Analysts' target$37.00average of analysts' targets
Current price—

Targets, low to high

$37.00

Low $32.00

Middle $37.00

High $42.00

More →

Earnings per share estimates

Per shareThis quarterMar 2025Next quarterJun 2025This yearYear to Dec 2024Next yearYear to Dec 2025
Average estimate−$58.89$165.45−$16.40−$156.13
Lowest estimate−$58.89$165.45−$16.40−$156.13
Highest estimate−$58.89$165.45−$16.40−$156.13
Number of analysts1111
A year ago————
Growth vs a year ago————

Revenue estimates

TotalThis quarterMar 2025Next quarterJun 2025This yearYear to Dec 2024Next yearYear to Dec 2025
Average estimate$50.00M$50.00M$50.00M$0.00
Lowest estimate$50.00M$50.00M$50.00M$0.00
Highest estimate$50.00M$50.00M$50.00M$0.00
Number of analysts11—0
A year ago————
Growth vs a year ago————
Recent rating and target changes (2)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Obsidian Therapeutics Inc.. Obsidian Therapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold OBX12 companies · 6 funds
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
AGMBAgomAb Therapeutics N.V. American Depositary SharesHealthcareNASDAQ$313.2M
AGN.AXArgenica Therapeutics LtdHealthcareASX—
AGNPFAlgernon Pharmaceuticals Inc.HealthcareOTC$1.1M
AGTXAgentix Corp.HealthcareOTC$1.9M
AIMAIM ImmunoTech Inc.HealthcareAMEX$5.7M
AIMDAinos, Inc.HealthcareNASDAQ$9.1M
AIMDWAinos, Inc.HealthcareNASDAQ$2.7M
AKBAAkebia Therapeutics, Inc.HealthcareNASDAQ$131.7M
AKBLFALK-Abelló A/SHealthcareOTC$7.3B
AKTXAkari Therapeutics, PlcHealthcareNASDAQ$15.6M
ALA.AXArovella Therapeutics LimitedHealthcareASX—
ALDXAldeyra Therapeutics, Inc.HealthcareNASDAQ$38.9M
ETFs holding Obsidian Therapeutics Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.01%
SCHASchwab U.S. Small-Cap ETF$21.7B in assets0.01%
GISCGuggenheim Funds Trust - Guggenheim Securitized Income ETF$93M in assets0.09%
ITOTiShares Core SP Total US Stock Market ETF$93.2B in assets0.00%
SCHBSchwab U.S. Broad Market ETF$43.2B in assets0.00%

Largest holders first, then the funds most concentrated in OBX.

Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Obsidian Therapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Obsidian Therapeutics Inc.. Coverage tracks Obsidian Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Obsidian Therapeutics Inc.

OBX AnalysisWeak
Past
3
Growth
1
Health
1
Profit
1
Value
1